comparemela.com

Latest Breaking News On - பொருளாதார விமர்சனம் - Page 8 : comparemela.com

Questions Surround Biogen s New Alzheimer s Drug

Biogen’s Aducanumab is the first FDA approved drug that’s supposed to treat an underlying cause of Alzheimer’s Disease, but many scientists aren’t convinced that it can actually do that. The company’s clinical trials of the drug sparked a debate over whether the drug really works, and how much patients should pay for it. WBUR’s Angus Chen attended the Boston-based Institute for Clinical and Economic Review or ICER’s hearing on Thursday, where an independent panel of scientists considered whether the Alzheimer’s drug is beneficial to patients and worth the price. This segment aired on July 16, 2021.

Aduhelm: The hard math on the new $56,000 Alzheimer s drug

Aduhelm: The hard math on the new $56,000 Alzheimer s drug CNN 2 hrs ago Analysis by Zachary B. Wolf, CNN © BSIP/UIG/Getty Images Late Onset Alzheimer s Disease Senile Dementia. Symmetric Enlargement Of Cerebral Sulci Suggests That Cortical Gray Matter Is Affected. Axial Cut Away View. (Photo By BSIP/UIG Via Getty Images) The new Alzheimer s drug Aduhelm costs $56,000 per person, per year so much that it would affect the economics of Medicare. The US Food and Drug Administration granted maker Biogen special approval despite concerns regarding evidence about how well the drug, technically called aducanumab, even works leading to immediate backlash:

© 2025 Vimarsana

vimarsana © 2020. All Rights Reserved.